Top

memo - Magazine of European Medical Oncology

Published in:

Open Access 23-08-2023 | Radiotherapy | short review

New developments in radiation oncology for head and neck cancers

Authors: Christoph Resl, Petra Georg, Carmen Döller

Published in: memo - Magazine of European Medical Oncology | Issue 3/2023

Summary

Treatment of head and neck cancers is multidisciplinary involving surgery, radiotherapy and systemic treatment. The disease outcome depends on multiple factors involving tumour biology and behaviour as well patient’s clinical condition and comorbidities. Taking into account all these factors, the treatment decision should be tailored according to tumour characteristics and patient’s needs. Treatment could be de-intensified on the one hand, or intensified on the other hand, with the aim to achieve the best therapeutic outcome. New developments in radiation oncology shift the focus toward personalised patient treatment including clinical information, multimodality imaging and early assessments of treatment response to adapt the treatment.

Budach V, Tinhofer I. Novel prognostic clinical factors and biomarkers for outcome prediction in head and neck cancer: a systematic review. Lancet Oncol. 2019;20:e313–e26.CrossRefPubMed

Bigelow EO, Seiwert TY, Fakhry C. Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: Current state and future directions. Oral Oncol. 2020;105:104652. https://doi.org/10.1016/j.oraloncology.2020.104652.CrossRefPubMedPubMedCentral

Mensour EA, Alam S, Mawani S, et al. What is the future of treatment de-escalation for HPV-positive oropharyngeal cancer? A review of ongoing clinical trials. Front Oncol. 2022;12:1067321. https://doi.org/10.3389/fonc.2022.1067321.CrossRefPubMedPubMedCentral

Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial. Lancet. 2019;393:40–50. https://doi.org/10.1016/S0140-6736(18)32779-X.CrossRefPubMed

Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label randomised controlled phase 3 trial. Lancet. 2019;393(10166):51–60. https://doi.org/10.1016/S0140-6736(18)32752-1.CrossRefPubMedPubMedCentral

Rischin D, King M, Kenny L, Porceddu S, et al. Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01)—A Trans-Tasman radiation Oncology Group study. Int J Radiat Oncol Biol Phys. 2021;111(4):876–86. https://doi.org/10.1016/j.ijrobp.2021.04.015.CrossRefPubMed

Chera BS, Amdur RJ, Tepper J, et al. Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human Papillomavirus-associated oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2015;93(5):976–85. https://doi.org/10.1016/j.ijrobp.2015.08.033.CrossRefPubMed

Chera BS, Amdur RJ, Green R, et al. Phase II trial of de-intensified chemoradiotherapy for human Papillomavirus—Associated oropharyngeal squamous cell carcinoma. J Clin Oncol. 2019;37(29):2661–9. https://doi.org/10.1200/JCO.19.01007.CrossRefPubMedPubMedCentral

Yom SS, Torres-Saavedra P, Caudell JJ, et al. Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG oncology HN002). J Clin Oncol. 2021;39(9):956–65. https://doi.org/10.1200/JCO.20.03128.CrossRefPubMedPubMedCentral

10.

Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021;22(4):450–62. https://doi.org/10.1016/S1470-2045(20)30737-3.CrossRefPubMed

11.

Tao Y, Aupérin A, Sun X, et al. Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH). Eur J Cancer. 2020;141:21–9. https://doi.org/10.1016/j.ejca.CrossRefPubMed

12.

Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011;12(2):127–36. https://doi.org/10.1016/S1470-2045(10)70290-4.CrossRefPubMedPubMedCentral

13.

Mehanna H, Rischin D, Wong SJ, et al. De-escalation after DE-ESCALATE and RTOG 1016: a head and neck cancer intergroup framework for future de-escalation studies. J Clin Oncol. 2020;38(22):2552–7. https://doi.org/10.1200/JCO.20.00056.CrossRefPubMedPubMedCentral

14.

Mulder SL, Heukelom J, McDonald BA, et al. MR-guided adaptive radiotherapy for OAR sparing in head and neck cancers. Cancers (Basel). 2022;14(8):1909. https://doi.org/10.3390/cancers14081909.CrossRefPubMed

15.

Ridder M, Raaijmakers CPJ, Pameijer FA, et al. Target definition in MR-guided adaptive radiotherapy for head and neck cancer. Cancers (Basel). 2022;14(12):3027–3020. https://doi.org/10.3390/cancers14123027.CrossRefPubMed

16.

van Timmeren JE, Chamberlain M, Bogowicz M, et al. MR-guided adaptive radiotherapy for head and neck cancer: prospective evaluation of migration and anatomical changes of the major salivary glands. Cancers (Basel). 2021;13(21):5404. https://doi.org/10.3390/cancers13215404.CrossRefPubMed

17.

Lavigne D, Ng SP, O’Sullivan B, et al. Magnetic resonance-guided radiation therapy for head and neck cancers. Curr Oncol. 2022;29(11):8302–15. https://doi.org/10.3390/curroncol29110655.CrossRefPubMedPubMedCentral

18.

Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35. https://doi.org/10.1056/NEJMoa0912217.CrossRefPubMedPubMedCentral

19.

Chow LQM. Head and neck cancer. N Engl J Med. 2020;382(1):60–72. https://doi.org/10.1056/NEJMra1715715.CrossRefPubMed

20.

Sun XS, Tao Y, Le Tourneau C, et al. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study. Lancet Oncol. 2020;21(9):1173–87. https://doi.org/10.1016/S1470-2045(20)30327-2.CrossRefPubMed

21.

Tao Y, Sun XS, Pointreau Y, et al. Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial. Eur J Cancer. 2023;183:24–37. https://doi.org/10.1016/j.ejca.2022.12.015.CrossRefPubMed

22.

Machiels JP, Tao Y, Burtness B, et al. LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2022. https://doi.org/10.1016/j.annonc.2022.08.029.CrossRefPubMed

23.

Lacas B, Carmel A, Landais C, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol. 2021;156:281–93. https://doi.org/10.1016/j.radonc.2021.01.013.CrossRefPubMedPubMedCentral

24.

Noronha V, Sharma V, Joshi A, et al. Carboplatin-based concurrent chemoradiation therapy in locally advanced head and neck cancer patients who are unfit for cisplatin therapy. Indian J Cancer. 2017;54(2):453–7. https://doi.org/10.4103/ijc.IJC_320_17.CrossRefPubMed

25.

Patil VM, Noronha V, Menon N, et al. Results of phase III randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemoradiation. J Clin Oncol. 2023; https://doi.org/10.1200/JCO.22.00980.CrossRefPubMed

Title: New developments in radiation oncology for head and neck cancers
Authors: Christoph Resl
Petra Georg
Carmen Döller
Publication date: 23-08-2023
Publisher: Springer Vienna
Keywords: Radiotherapy
Cytostatic Therapy
Published in: memo - Magazine of European Medical Oncology / Issue 3/2023
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-023-00914-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 3/2023

American Society of Hematology meeting update

Aggressive B cell lymphomas—highlights from ASH 2022

How the long-term follow-up is organized in young adult survivors of childhood cancer

Hepatosplenic T-cell lymphoma with hemophagocytic lymphohistiocytosis, revealed by fever of unknown origin

Late complications after oncological therapy

ASH highlights 2022—multiple myeloma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer